Cedric Rossi

List of Publications by Year
in descending order

59
papers	2,063
citations	257450
24
h-index	254184
43
g-index
61
all docs	61
docs citations	61
times ranked	3372
citing authors

#	Article	IF	Citations
1	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 5607-5615.	5.2	222
2	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
3	Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1735-1743.	6.4	152
4	Prolonged inâ€hospital stay and higher mortality after Covidâ€19 among patients with <scp>nonâ€Hodgkin</scp> lymphoma treated with Bâ€cell depleting immunotherapy. American Journal of Hematology, 2021, 96, 934-944.	4.1	110
5	Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases. Human Mutation, 2014, 35, 15-26.	2.5	101
6	Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma. PLoS ONE, 2015, 10, e0140830.	2.5	90
7	Efficacy of chemotherapy or chemoâ€antiâ€PDâ€1 combination after failed antiâ€PDâ€1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers. American Journal of Hematology, 2018, 93, 1042-1049.	4.1	87
8	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget, 2017, 8, 44960-44975.	1.8	82
9	Interim ^{18}F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients. Journal of Nuclear Medicine, 2014, 55, 569-573.	5.0	76
10	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood, 2021, 137, 877-887.	1.4	68
11	Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a populationâ€based study of 327 patients. British Journal of Haematology, 2013, 160, 251-254.	2.5	63
12	Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 445-449.	2.0	62
13	Accurate diagnosis of lymphoma on whole-slide histopathology images using deep learning. Npj Digital Medicine, 2020, 3, 63.	10.9	56
14	Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. EClinicalMedicine, 2020, 27, 100549.	7.1	55
15	Boosting Î³Î´ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. OncoImmunology, 2019, 8, 1554175.	4.6	53
16	Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells. Cell Reports, 2019, 26, 94-107.e7.	6.4	42
17	Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?). European Journal of Haematology, 2013, 91, 361-368.	2.2	38
18	Epidemiology, clinical picture and longâ€term outcomes of <i>FIP1L1â€PDGFRA</i>â€positive myeloid neoplasm with eosinophilia: Data from 151 patients. American Journal of Hematology, 2020, 95, 1314-1323.	4.1	37

#	Article	IF	Citations
19	Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins. Frontiers in Immunology, 2017, 8, 1347.	4.8	33
20	CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies. Blood, 2020, 136, 2428-2436.	1.4	32
21	First–line treatment of double–hit and triple–hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. American Journal of Hematology, 2021, 96, 302-311.	4.1	32
22	Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens. JCI Insight, 2017, 2, .	5.0	32
23	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica, 2020, 105, 1032-1041.	3.5	29
24	Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica, 2015, 100, 472-478.	3.5	28
25	Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Advances, 2021, 5, 3227-3239.	5.2	28
26	Clinical and economic impact of pharmacist interventions in an ambulatory hematology–oncology department. Journal of Oncology Pharmacy Practice, 2020, 26, 1172-1179.	0.9	27
27	A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. Frontiers in Immunology, 2019, 10, 1943.	4.8	22
28	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood, 2021, 137, 3495-3506.	1.4	22
29	Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining. Cancers, 2018, 10, 415.	3.7	19
30	Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. Blood Advances, 2021, 5, 3862-3872.	5.2	19
31	Baseline SUV$_{max}$ is related to tumor cell proliferation and patient outcome in follicular lymphoma. Haematologica, 2022, 107, 221-230.	3.5	17
32	[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives. Cancers, 2018, 10, 145.	3.7	16
33	Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma. Leukemia and Lymphoma, 2015, 56, 2876-2882.	1.3	13
34	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget, 2016, 7, 85573-85583.	1.8	13
35	Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review. Targeted Oncology, 2018, 13, 287-308.	3.6	12
36	Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. Journal of Clinical Oncology, 2022, 40, 1091-1101.	1.6	11

#	Article	IF	Citations
37	Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management. Leukemia and Lymphoma, 2014, 55, 1939-1941.	1.3	9
38	A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the â€œREal world dAta in LYmphoma and survival in adultsâ€•(REALYSA) cohort. BMC Public Health, 2021, 21, 432.	2.9	9
39	3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma. Cancers, 2021, 13, 1490.	3.7	9
40	Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas. Diagnostics, 2022, 12, 417.	2.6	9
41	Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients. Blood, 2019, 134, 1530-1530.	1.4	8
42	Monte Carlo dosimetry of a realistic multicellular model of follicular lymphoma in a context of radioimmunotherapy. Medical Physics, 2020, 47, 5222-5234.	3.0	5
43	Outcomes of pregnancy in patients with congenital erythrocytosis. British Journal of Haematology, 2015, 170, 586-588.	2.5	3
44	PD-1 inhibitors inÂpatients with Hodgkin lymphoma. European Journal of Cancer, 2022, 164, 114-116.	2.8	3
45	Extreme hyperferritinemia in the setting of acute myeloid leukaemia: a case report of hemophagocytic lymphohistiocytosis. Biochemia Medica, 2016, 26, 255-259.	2.7	3
46	Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax. Blood, 2019, 134, 807-807.	1.4	2
47	R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers. Blood, 2020, 136, 20-21.	1.4	2
48	Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT. Oncotarget, 2017, 8, 85110-85119.	1.8	2
49	Perirenal fibrosis: make your diagnosis. CKJ: Clinical Kidney Journal, 2013, 6, 543-544.	2.9	1
50	Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21). Journal of Physical Education and Sports Management, 2021, 7, a005934.	1.2	1
51	A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study. Blood, 2019, 134, 4762-4762.	1.4	1
52	PVAG Regimen (Prednisone, Vinblastine, Doxorubicin, Gemcitabine) Used in Real-Life Setting in First Line Therapy for Elderly Classical Hodgkin Lymphoma Patients: A Retrospective Study of Lysa Centers. Blood, 2020, 136, 11-11.	1.4	1
53	PET-guided treatment in advanced-stage Hodgkin lymphoma: yes but which one?. Oncotarget, 2019, 10, 4354-4355.	1.8	1
54	Somatic Mutation Profile Analyzed By Next-Generation Sequencing in Relapsed/Refractory Follicular Lymphoma Treated with Idelalisib. Blood, 2019, 134, 1503-1503.	1.4	1

#	Article	IF	Citations
55	Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients. Cancers, 2022, 14, 2532.	3.7	1
56	Comparison Of Hevyliteâ„¢ Assay and Plasma Cell Immunophenotyping For Response Evaluation and Residual Disease Characterisation In IgA Myeloma. Blood, 2013, 122, 5319-5319.	1.4	0
57	A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers. Blood, 2018, 132, 1629-1629.	1.4	0
58	Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response. Blood, 2019, 134, 128-128.	1.4	0
59	Extranodal classical Hodgkin lymphoma involving the spinal cord: case report and review of the literature. CNS Oncology, 0, , .	3.0	0